Alzheimer's disease and control brain contain soluble derivatives of the amyloid protein precursor that end within the .beta. amyloid protein region

J. M. Pasternack, Mark R. Palmert(Case Western Reserve University), M. Usiak(Case Western Reserve University), Rong Wang(Johns Hopkins University), Heidi A. Zürcher-Neely(Pfizer (United States)), Patricia A. Gonzalez‐DeWhitt(Johns Hopkins University), Michael B. Fairbanks(Pfizer (United States)), Tobun T. Cheung(Case Western Reserve University), Deborah Blades(Case Western Reserve University)
Biochemistry
November 1, 1992
Cited by 25

Abstract

The 39-43 amino acid beta amyloid protein (A beta) that deposits as amyloid in the brains of patients with Alzheimer's disease (AD) is encoded as an internal sequence within a larger membrane-associated protein known as the amyloid protein precursor (APP). In cultured cells, the APP is normally cleaved within the A beta to generate a large secreted derivative and a small membrane-associated fragment. Neither of these derivatives can produce amyloid because neither contains the entire A beta. Our study was designed to determine whether the soluble APP derivatives in human brain end within the A beta as described in cell culture or whether AD brain produces potentially amyloidogenic soluble derivatives that contain the entire A beta. We find that both AD and control brain contain nonamyloidogenic soluble derivatives that end at position 15 of the A beta. We have been unable to detect any soluble derivatives that contain the entire A beta in either the AD or control brain.


Related Papers

No related papers found

Powered by citation graph analysis